Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Khatri, Neetu"'
Autor:
Khatri, Monika, Mantri, Sneha, Deogade, Suryakant, Bhasin, Abhilasha, Mantri, Shivkumar, Khatri, Neetu, Jain, Priyanka, Chauhan, Deepak
Publikováno v:
Contemporary Clinical Dentistry; Jan-Mar2020, Vol. 11 Issue 1, p10-14, 5p
Publikováno v:
Journal of Drug Delivery & Therapeutics; 2018 Supplement, Vol. 8, p350-358, 9p
Publikováno v:
Journal of Biological & Scientific Opinion. 1:263-270
Abstrac t Oral controlled release drug delivery system becomes a very promising approach for those drugs that are given orally but having the high dosing frequency and shorter half - life. Matrix tablets serves as an important tool for oral controlle
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e53aab233004d78166e698978b9f918c
https://doi.org/10.7897/2321-6328.01328
https://doi.org/10.7897/2321-6328.01328
Autor:
Saud, Bhuvan1 (AUTHOR), Khatri, Gita1 (AUTHOR), Amatya, Neetu1 (AUTHOR), Paudel, Govinda1 (AUTHOR), Shrestha, Vikram1 (AUTHOR)
Publikováno v:
Canadian Journal of Infectious Diseases & Medical Microbiology. 1/4/2023, p1-6. 6p.
Publikováno v:
Pharma Science Monitor. Apr-Jun2018, Vol. 9 Issue 2, p283-300. 18p.
Autor:
Patel, Pinal M.1, Yadav, Jitendrasingh1
Publikováno v:
Pharma Science Monitor. Jan-Mar2018, Vol. 9 Issue 1, p697-718. 22p.
Autor:
Ujjwol Khatri, Neetu Dayal, Xueqing Hu, Elizabeth Larocque, Nimishetti Naganna, Tao Shen, Xuan Liu, Frederick W. Holtsberg, M. Javad Aman, Herman O. Sintim, Jie Wu
Publikováno v:
Cancer Research. 83:3851-3851
Selpercatinib (LOXO-292, LY3527723) and pralsetinib (BLU-667) are first-in-class RET-targeted cancer therapy drugs. However, secondary RET mutations that confer selpercatinib/pralsetinib resistance have been identified, necessitating development of n
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ba953ceface7469585953d0652cd2c1d
https://doi.org/10.1158/1538-7445.am2023-3851
https://doi.org/10.1158/1538-7445.am2023-3851